My Portfolio
+
LINK YOUR PORTFOLIO

Corcept Therapeutics Inc CORT:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:00 PM EDT
72.65UNCH (UNCH)
Volume
15,045
Close
72.65quote price arrow up+1.45 (+2.04%)
Volume
778,164
52 week range
28.66 - 91.00
Loading...
  • Open70.93
  • Day High72.95
  • Day Low70.07
  • Prev Close71.20
  • 52 Week High91.00
  • 52 Week High Date10/08/25
  • 52 Week Low28.66
  • 52 Week Low Date02/19/26

Key Stats

  • Market Cap7.799B
  • Shares Out107.35M
  • 10 Day Average Volume1.06M
  • Dividend-
  • Dividend Yield-
  • Beta0.50

KEY STATS

  • Open70.93
  • Day High72.95
  • Day Low70.07
  • Prev Close71.20
  • 52 Week High91.00
  • 52 Week High Date10/08/25
  • 52 Week Low28.66
  • 52 Week Low Date02/19/26
  • Market Cap7.799B
  • Shares Out107.35M
  • 10 Day Average Volume1.06M
  • Dividend-
  • Dividend Yield-
  • Beta0.50

RATIOS/PROFITABILITY

  • EPS (TTM)0.35
  • P/E (TTM)204.82
  • Fwd P/E (NTM)73.91
  • EBITDA (TTM)-6.758M
  • ROE (TTM)7.17%
  • Revenue (TTM)769.096M
  • Gross Margin (TTM)98.25%
  • Net Margin (TTM)6.16%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date07/29/2026(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients...
James Wilson
Independent Chairman of the Board
Joseph Belanoff M.D.
President, Chief Executive Officer, Co-Founder, Director
Atabak Mokari
Chief Financial Officer, Treasurer
Joseph Lyon
Chief Accounting and Technology Officer
Address
101 REDWOOD SHORES PARKWAY
Redwood City, CA
94065
United States